News
Monthly weight-loss shots on the horizon! Learn about new drugs like MariTide and why Black participation in clinical trials ...
MariTide helped participants lose up to 20% of their body weight in a year-long trial. But it could be years before the new ...
Amgen's long-acting experimental obesity drug MariTide needs to be given at a low starting dose to limit side effects like ...
The drug, MariTide, also helped patients with obesity and Type 2 diabetes lose up to 17% of their weight after a year. The company said it did not observe a plateau in either group of patients ...
Eli Lilly and Novo Nordisk, which already have approved GLP-1 weight loss drugs that are raking in billions of revenues, have ...
Amgen plans to proceed with Phase 3 trials, initiating patients on a lower dosage that will gradually increase over an eight-week period.
Amgen has said it has no concerns about MariTide's bone density data. Trial design The first part of the phase two trial followed 592 patients, including 465 patients with obesity and 127 with ...
Amgen's weight-loss drug MariTide had a successful Phase 2 trial so the company is expanding development plans to study its use for heart disease and sleep apnea.
Amgen continues to investigate MariTide in the Phase 2 trial (Part 2), monitoring its effects beyond 52 weeks. They are also optimizing weight maintenance through less frequent or lower dosing ...
Amgen released the long-awaited results from its study of weight loss injection MariTide and the results — while promising — are still being evaluated by industry stakeholders. The pharma giant ...
Hosted on MSN11mon
Amgen's MariTide Weight Loss Potential: Stock Outlook - MSNAmgen (NASDAQ: AMGN) is a biotechnology firm that has made its way into the weight loss treatment battle. The company’s shares have performed relatively well in 2024, providing a total return of ...
Amgen posted a higher quarterly profit on Tuesday as product sales rose 11% and said late-stage studies of key obesity drug candidate MariTide will start before mid-year but regulators have placed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results